Head Of Rx Drug Makers Group Says Obama Budget Plans Cause Concern
John Castellani, the head of the Pharmaceutical Research and Manufacturers of America, notes support for health overhaul but says efforts to change Medicare Part D program and companies’ control of biologic drugs “would do serious harm to our industry.”